Results 251 to 260 of about 2,899,588 (264)

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer

Annals of Oncology, 2018
Rebecca J. Watters, Adam Brufsky, Adrian V Lee   +2 more
exaly  

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Annals of Oncology, 2019
Fabrice André, Arlindo R Ferreira, Stefan Michiels   +2 more
exaly  

Hormone production in non-endocrine tumors

Ca-A Cancer Journal for Clinicians, 1977
Naguib A Samaan, N A Samaan
exaly  

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

Annals of Oncology, 2007
M Beeram
exaly  

Managing side effects in adjuvant endocrine therapy for breast cancer

Expert Review of Anticancer Therapy, 2018
Ines Vaz-Luis
exaly  

Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer

Annals of Oncology, 2013
Anne Stiggelbout, M L Bouvy, M L Bouvy
exaly  

A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma

Annals of Oncology, 2019
W T Barry, M Koehler, A Demichele
exaly  

Endocrine Therapy of Advanced Breast Cancer

Acta Oncológica, 1988
H T Mouridsen
exaly  

Patients’ preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?

British Journal of Cancer, 2005
Christobel Saunders, L J Fallowfield, A S Coates   +2 more
exaly  

The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer

European Journal of Cancer, 1997
Kwok-Leung Cheung, J F R Robertson, P C Willsher   +2 more
exaly